Compare

Protagenic Therapeutics, Inc.new vs Pulmatrix, Inc. vs Cadrenal Therapeutics, Inc. vs Hepion Pharmaceuticals, Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearProtagenic Therapeutics, Inc.new
PTIXRevenue covers only part of its income (partial revenue)
Pulmatrix, Inc.
PULM
Cadrenal Therapeutics, Inc.
CVKD
Hepion Pharmaceuticals, Inc.
HEPA
Year ended2026-03-312025-12-312025-12-312025-12-31
Revenuen/an/an/an/a
Revenue growth (YoY)n/an/an/an/a
Gross marginn/an/an/an/a
Operating marginn/an/an/an/a
Net marginn/an/an/an/a
Net income$1.37M-$5.16M-$13.24M-$8.28M
EPS (Diluted)$0.59-$1.41-$6.64-$0.88
Operating cash flow-$2.81M-$5.43M-$12.60M-$3.27M
Free cash flow-$2.81Mn/a-$12.61Mn/a
Cash & equivalentsn/a$4.09M$4.01Mn/a
Total assets$3.65M$4.14M$4.33M$3.07M
Total liabilities$1.03M$329.0K$1.59M$402.4K
Shareholders' equity$2.62M$3.81M$2.74M$2.67M
Return on year-end equity52.2%-135.5%-483.3%-310.3%
Shares outstanding1.81M3.65M2.34M11.62M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearProtagenic Therapeutics, Inc.newPulmatrix, Inc.Cadrenal Therapeutics, Inc.Hepion Pharmaceuticals, Inc.
Latestn/a$7.81M
Ended 2024-12-31
n/a$0
Ended 2023-12-31
1 year earliern/a$7.30M
Ended 2023-12-31
n/a$0
Ended 2022-12-31
2 years earliern/a$6.07M
Ended 2022-12-31
n/a$0
Ended 2021-12-31
3 years earliern/a$5.17M
Ended 2021-12-31
n/a$0
Ended 2020-12-31
4 years earliern/a$12.63M
Ended 2020-12-31
n/an/a